-
公开(公告)号：US20230330198A1
公开(公告)日：2023-10-19
申请号：US18333273
申请日：2023-06-12
Applicant: BioNTech SE , TRON - Translationale Onkologie an der Universitatsmedizin der Johannes Gutenberg-Universitat Mainz
Inventor： Ugur Sahin , Sebastian Kreiter , Christina Krienke , Jutta Petschenka , Lena Mareen Kranz , Mustafa Diken
IPC: A61K39/00 , A61P37/06 , C12N15/11 , C12N15/117
CPC classification number: A61K39/0008 , A61P37/06 , C12N15/11 , C12N15/117 , A61K2039/53 , A61K2039/55555 , C12N2310/335
Abstract: The present invention relates to non-immunogenic RNA. This RNA forms the basis for the development of therapeutic agents for inducing tolerance towards an autoantigen and thus, for the treatment of autoimmune diseases.
-
公开(公告)号：US12150947B2
公开(公告)日：2024-11-26
申请号：US16957898
申请日：2019-01-10
Applicant: BioNTech SE , TRON—TRANSLATIONALE ONKOLOGIE AN DER UNIVERSITATSMEDIZIN DER JOHANNES GUTENBERG-UNIVERSITAT MAINZ GGMBH
Inventor： Ugur Sahin , Heinrich Haas , Annette Vogel , Stephanie Erbar , Kerstin Walzer , Anne Schlegel , Sebastian Hörner , Jorge Herrero Moreno , Thorsten Klamp , Sebastian Kreiter , Mustafa Diken , Phillip Heller
IPC: A61K31/70 , A61K9/00 , A61K35/763 , A61K47/18
Abstract: The present invention relates to compositions comprising polyplex formulations for delivery of RNA to a target organ or a target cell after parenteral administration, in particular after intramuscular administration. More precisely, the present invention relates to formulations for administration of RNA such as self-replicating RNA, in particular by intramuscular injection. In more detail, the formulations comprise polyplex particles from single stranded RNA and a polyalkyleneimine.
-
公开(公告)号：US11701413B2
公开(公告)日：2023-07-18
申请号：US16500005
申请日：2018-04-10
Applicant: BioNTech SE , TRON—Translationale Onkologie an der Universitätsmedizin der Johannes Gutenberg-Universität Mainz gemeinnützige GmbH
Inventor： Ugur Sahin , Sebastian Kreiter , Christina Krienke , Jutta Petschenka , Lena Mareen Kranz , Mustafa Diken
IPC: A61K39/00 , A61P37/06 , C12N15/11 , C12N15/117
CPC classification number: A61K39/0008 , A61P37/06 , C12N15/11 , C12N15/117 , A61K2039/53 , A61K2039/55555 , C12N2310/335
Abstract: The present invention relates to non-immunogenic RNA. This RNA forms the basis for the development of therapeutic agents for inducing tolerance towards an autoantigen and thus, for the treatment of autoimmune diseases.
-
公开(公告)号：US20220378876A1
公开(公告)日：2022-12-01
申请号：US17763329
申请日：2020-09-22
Applicant: BioNTech SE , Tron-Translationale Onkologie An Der Universitatsmedizin Der Johannes Gutenberg-Universitat Mainz
Inventor： Ugur Sahin , Mathias Vormehr , Jan David Beck , Mustafa Diken , Sebastian Kreiter
IPC: A61K38/20 , A61K39/39 , A61K39/395 , A61K45/06 , A61P35/00
Abstract: Tumor cells often evade an immune response, e.g., by reducing or eliminating MHC expression and/or IFN-signaling, which enables uncontrolled growth. We demonstrate herein that antibody-based immunotherapy in combination with IL2 administration is an effective therapy against such resistant tumors. Specifically, the present disclosure relates to methods of treating a subject with cancer that is at least partially resistant to an MHC-dependent T cell response comprising administering to the subject: a. a polypeptide comprising IL2 or a functional variant thereof or a polynucleotide encoding a polypeptide comprising IL2 or a functional variant thereof; and b. antibody-based immunotherapy.
-
公开(公告)号：US20220257783A1
公开(公告)日：2022-08-18
申请号：US17688707
申请日：2022-03-07
Applicant: BioNTech SE
Inventor： Ozlem Tureci , Ugur Sahin , Sebastian Kreiter
Abstract: The present invention relates to fusion molecules of antigens, the nucleic acids coding therefor and the use of such fusion molecules and nucleic acids. In particular, said invention relates to fusion molecules, comprising an antigen and the trans-membrane region and cytoplasmic region of a MHC molecule and/or the cytoplasmic region of a MHC or a SNARE molecule.
-
Patent Agency Ranking
6.发明公开公开(公告)号：US20230193296A1
公开(公告)日：2023-06-22
申请号：US18049593
申请日：2022-10-25
Applicant: BioNTech SE
Inventor： Ugur Sahin , Silke Holtkamp , Ozlem Tureci , Sebastian Kreiter
Abstract: It was the object of the present invention to provide RNA with increased stability and translation efficiency and means for obtaining such RNA. It should be possible to obtain increased grades of expression by using said RNA in gene therapy approaches.
-
公开(公告)号：US11559587B2
公开(公告)日：2023-01-24
申请号：US16578601
申请日：2019-09-23
Applicant: BioNTech SE , TRON—Translationale Onkologie an der Universitätsmedizin der Johannes Gutenberg—Universität Mainz gGmbH
Inventor： Ugur Sahin , Heinrich Haas , Sebastian Kreiter , Mustafa Diken , Daniel Fritz , Martin Meng , Lena Mareen Kranz , Kerstin Reuter
Abstract: The present invention is in the field of immunotherapy, in particular tumor immunotherapy. The present invention provides pharmaceutical formulations for delivering RNA to antigen presenting cells such as dendrite cells (DCs) in the spleen after systemic administration. In particular, the formulations described herein enable to induce an immune response after systemic administration of antigen-coding RNA.
-
公开(公告)号：US11298426B2
公开(公告)日：2022-04-12
申请号：US15895402
申请日：2018-02-13
Applicant: BioNTech SE
Inventor： Ozlem Tureci , Ugur Sahin , Sebastian Kreiter
Abstract: The present invention relates to fusion molecules of antigens, the nucleic acids coding therefor and the use of such fusion molecules and nucleic acids. In particular, said invention relates to fusion molecules, comprising an antigen and the trans-membrane region and cytoplasmic region of a MHC molecule and/or the cytoplasmic region of a MHC or a SNARE molecule.
-
公开(公告)号：US20220282322A1
公开(公告)日：2022-09-08
申请号：US17576170
申请日：2022-01-14
Applicant: TRON-Translationale Onkologie an der Universitätsmedizin der Johannes Gutenberg-Universität Mainz gG , BioNTech SE
Inventor： Ugur Sahin , Sebastian Kreiter , Mustafa Diken , Jan Diekmann , Michael Koslowski , Cedrik Britten , John Christopher Castle , Martin Löwer , Bernhard Renard , Tana Omokoko , Johannes Hendrikus De Graaf
IPC: C12Q1/6869 , A61K39/00 , G16B20/00 , G16B40/00 , C12Q1/6886 , G16B20/20
Abstract: The present invention relates to the provision of vaccines which are specific for a patient's tumor and are potentially useful for immunotherapy of the primary tumor as well as tumor metastases. In one aspect, the present invention relates to a method for providing an individualized cancer vaccine comprising the steps: (a) identifying cancer specific somatic mutations in a tumor specimen of a cancer patient to provide a cancer mutation signature of the patient; and (b) providing a vaccine featuring the cancer mutation signature obtained in step (a). In a further aspect, the present invention relates to vaccines which are obtainable by said method.
-
公开(公告)号：US20220249372A1
公开(公告)日：2022-08-11
申请号：US17727956
申请日：2022-04-25
Applicant: BioNTech SE , Tron-Translationale Onkologie an der Universitatsmedizin der Johannes Gutenberg-University Mainz Gmb
Inventor： Hossam Hefesha , Ugur Sahin , Heinrich Haas , Sebastian Kreiter , Yves Hüsemann , Mustafa Diken , Kerstin Walzer
IPC: A61K9/107 , A61K9/127 , A61K48/00 , A61K31/675 , A61K31/7105 , A61K9/00 , A61K31/663 , A61K45/06 , A61K39/395 , A61P35/00 , A61K39/00 , A61K47/18 , A61K47/24
Abstract: The present invention relates to lipid particles comprising at least one cationic lipid, at least one water-soluble therapeutically effective compound and RNA. Further, the present invention relates to a pharmaceutical composition comprising such particles. Said pharmaceutical composition is useful for inducing an immune response. It is also useful in a prophylactic and/or therapeutic treatment of a disease involving an antigen. Furthermore, the present invention relates to a method for producing the particles.
-
-
-
-
-
-
-
-
-
Search Results
14
records
(took 0.014 seconds)
